You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

JELMYTO Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Jelmyto, and what generic alternatives are available?

Jelmyto is a drug marketed by Urogen Pharma and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has nine patent family members in six countries.

The generic ingredient in JELMYTO is mitomycin. There are seven drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the mitomycin profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Jelmyto

A generic version of JELMYTO was approved as mitomycin by HIKMA on April 19th, 1995.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for JELMYTO?
  • What are the global sales for JELMYTO?
  • What is Average Wholesale Price for JELMYTO?
Summary for JELMYTO
International Patents:9
US Patents:2
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 1
Clinical Trials: 6
Patent Applications: 4,558
Drug Prices: Drug price information for JELMYTO
What excipients (inactive ingredients) are in JELMYTO?JELMYTO excipients list
DailyMed Link:JELMYTO at DailyMed
Drug patent expirations by year for JELMYTO
Drug Prices for JELMYTO

See drug prices for JELMYTO

Recent Clinical Trials for JELMYTO

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
City of Hope Medical CenterPhase 2
Mayo ClinicPhase 2
National Cancer Institute (NCI)Phase 2

See all JELMYTO clinical trials

Paragraph IV (Patent) Challenges for JELMYTO
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
JELMYTO Powder for Injection mitomycin 40 mg/vial 211728 1 2023-12-28

US Patents and Regulatory Information for JELMYTO

JELMYTO is protected by two US patents and one FDA Regulatory Exclusivity.

Patents protecting JELMYTO

Material and method for treating internal cavities
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Material and method for treating internal cavities
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

FDA Regulatory Exclusivity protecting JELMYTO

INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH LOW-GRADE UPPER TRACT UROTHELIAL CANCER (LG-UTUC)
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Urogen Pharma JELMYTO mitomycin POWDER;PYELOCALYCEAL 211728-001 Apr 15, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Urogen Pharma JELMYTO mitomycin POWDER;PYELOCALYCEAL 211728-001 Apr 15, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Urogen Pharma JELMYTO mitomycin POWDER;PYELOCALYCEAL 211728-001 Apr 15, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for JELMYTO

See the table below for patents covering JELMYTO around the world.

Country Patent Number Title Estimated Expiration
World Intellectual Property Organization (WIPO) 2011089604 ⤷  Sign Up
Israel 230530 חומרים ושיטה לטיפול בחללים של הגוף (Materials and method for treating internal body cavities) ⤷  Sign Up
Israel 221040 חומר ושיטה לטיפול בחללי גוף פנימיים (Material and method for treating internal cavities) ⤷  Sign Up
Denmark 2525777 ⤷  Sign Up
European Patent Office 2525777 MATÉRIEL ET PROCÉDÉ DE TRAITEMENT DE CAVITÉS INTERNES (MATERIAL AND METHOD FOR TREATING INTERNAL CAVITIES) ⤷  Sign Up
Germany 212011100034 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.